⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL2113580 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL27539486 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL634091 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL2113497 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL2114787 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL2112418 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL29180917 | 0.91 | — | — | |
| Trimethylammonium SCHEMBL27471374 | 0.91 | — | — | |
| Trimethylammonium SCHEMBL28807619 | 0.91 | — | — | |
| Trimethylammonium SCHEMBL27505093 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108681-B | Process for preparing substituted nucleoside analogues | 詹森生物制药有限公司 | 2021-04-06 | — | — | CN | claimed |
| US-6506682-B1 | Non-selective slurries for chemical mechanical polishing of metal layers and method for manufacturing thereof | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2003-01-14 | — | — | US | claimed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-3402801-B1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | INNATE TUMOR IMMUNITY INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12276037-B2 | Anodized titanium material and method for producing the same | YAMAGUCHI PREFECTURAL INDUSTRIAL TECHNOLOGY INSTITUTE (JP) | 2025-04-15 | — | — | US | disclosed |
| CN-112585302-B | Anodic titanium oxide material and method for producing same | 地方独立行政法人山口县产业技术研究院 | 2025-03-18 | — | — | CN | disclosed |
| US-12173215-B2 | MXene with excellent mechanical strength and fast and high-yield anhydrous synthesis method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-12-24 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3344644-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-115667257-B | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2006076674-A2 | DEPROTECTION AND PURIFICATION OF OLIGONUCLEOTIDES AND THEIR DERIVATIVES | SIRNA THERAPEUTICS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060111563-A1 | Deprotection and purification of oligonucleotides and their derivatives | SIRNA THERAPEUTICS, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-6989442-B2 | Deprotection and purification of oligonucleotides and their derivatives | SIRNA THERAPEUTICS, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050215777-A1 | Synthesizing nucleic acid, contacting with a alkylamine, loading mixture onto media and applying a purification gradient using a suitable elution buffer; one pot deprotection; solution phase synthesis; solid phase synthesis | SIRNA THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1539778-A2 | DEPROTECTION AND PURIFICATION OF OLIGONUCLEOTIDES AND THEIR DERIVATIVES | Sirna Therapeutics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040048251-A1 | Deprotection and purification of oligonucleotides and their derivatives | SIRNA THERAPEUTICS, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004007748-A2 | DEPROTECTION AND PURIFICATION OF OLIGONUCLEOTIDES AND THEIR DERIVATIVES | SIRNA THERAPEUTICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-0021331-B1 | PROCESS FOR PRODUCING SULFUR TETRAFLUORIDE | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-05-26 | — | — | EP | disclosed |
| EP-0021331-A1 | Process for producing sulfur tetrafluoride | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-01-07 | — | — | EP | disclosed |